epirubicin has been researched along with Neoplasms, Bone Marrow in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baak, JP; Gilje, B; Janssen, EA; Nordgård, O; Smaaland, R; Søiland, H; Tjensvoll, K | 1 |
Ariad, S; Bobilev, D; Geffen, DB; Tokar, M | 1 |
Abdallah, A; Bastert, G; Egerer, G; Fersis, N; Funk, L; Goldschmidt, H; Haas, R; Hahn, U; Hohaus, S; Kaul, S; Martin, S; Schlenk, RF; Schneeweiss, A; Wallwiener, D | 1 |
Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G | 1 |
2 trial(s) available for epirubicin and Neoplasms, Bone Marrow
Article | Year |
---|---|
Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitotic Index; Neoplasm Micrometastasis; Prognosis; Tamoxifen; Treatment Outcome | 2011 |
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Melatonin; Middle Aged; Platelet Count; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome | 1999 |
2 other study(ies) available for epirubicin and Neoplasms, Bone Marrow
Article | Year |
---|---|
Disseminated intravascular coagulation at presentation of advanced gastric cancer.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Bone Marrow Neoplasms; Cisplatin; Disease Progression; Disseminated Intravascular Coagulation; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Estrogen; Recombinant Proteins; Tamoxifen; Treatment Outcome | 1999 |